Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002022648 - COMPOSITIONS AND METHODS FOR INDUCING SPECIFIC CYTOLYTIC T CELL RESPONSES

Publication Number WO/2002/022648
Publication Date 21.03.2002
International Application No. PCT/US2001/028016
International Filing Date 06.09.2001
Chapter 2 Demand Filed 18.03.2002
IPC
C12N 5/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12Q 1/02 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
A61K 35/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/5154
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
A61K 2039/5158
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5158Antigen-pulsed cells, e.g. T-cells
A61K 2039/57
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
A61K 39/0011
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • ORTHO-MCNEIL PHARMACEUTICAL, INC. [US]/[US]
Inventors
  • VITIELLO, Antonella
  • MACCARIO, Rita
  • MONTAGNA, Daniela
Agents
  • WALLEN, John, W., III
Priority Data
60/233,00915.09.2000US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR INDUCING SPECIFIC CYTOLYTIC T CELL RESPONSES
(FR) COMPOSITIONS ET METHODES DESTINEES A INDUIRE DES REPONSES CYTOLYTIQUES SPECIFIQUES CHEZ DES LYMPHOCYTES T
Abstract
(EN)
The invention provides a method of inducing CD8+ T lymphocytes selective for a pathologically aberrant cell ex vivo. The method consists of contacting an apoptotic pathologically aberrant cell with a mixture having at least dendritic cells (DC), CD4+ T cells and CD8+ T lymphocytes, and culturing an apoptotic pathologically aberrant cell with the mixture for sufficient time to generate CD8+ T lymphocytes (TL) having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell. The invention further provides a method of inducing CD8+ TL selective for one or more target antigens ex vivo. The method consists of contacting one or more target antigens with a mixture having at least dendritic cells (DC), CD4+ T cells, CD8+ TL and IL-7, and culturing said one or more target antigens with the mixture for sufficient time to generate CD8+ TL having selective immune reactivity toward one or more target antigens. The invention further provides a method of treating a patient having a disease mediated by a pathologically aberrant cell. The method consists of administering an effective amount of a CD8+ TL produced by the methods of the invention having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell.
(FR)
La présente invention concerne une méthode d'induction de lymphocytes T CD8+ sélectifs vis à vis d'une cellule aberrante sur le plan pathologique ex vivo. Cette méthode consiste à mettre une cellule apoptotique aberrante sur le plan pathologique en contact avec un mélange renfermant au moins des cellules dendritiques (CD), des lymphocytes T CD4+ et des lymphocytes T CD8+, et à mettre une cellule apoptotique aberrante sur le plan pathologique en culture avec le mélange pendant un laps de temps suffisant pour générer des lymphocytes T (LT) CD8+ à spécificité antigénique et/ou à activité cytolytique sélective vis à vis d'une cellule aberrante sur le plan pathologique. L'invention concerne également une méthode d'induction de lymphocytes T CD8+ sélectifs vis à vis d'un ou de plusieurs antigènes cibles ex vivo. Cette méthode consiste à mettre un ou plusieurs antigènes cibles en contact avec un mélange renfermant au moins des cellules dendritiques (CD), des lymphocytes T CD4+, des lymphocytes T CD8+ et une IL-7, et à mettre ce ou ces antigènes cibles en culture avec le mélange pendant un laps de temps suffisant pour générer des lymphocytes T CD8+ présentant une réactivité immunologique sélective vis à vis d'un ou de plusieurs antigènes cibles. L'invention concerne également une méthode destinée au traitement d'un patient atteint d'une pathologie induite par une cellule aberrante sur le plan pathologique. Cette méthode consiste à administrer une dose efficace de lymphocytes T CD8+ selon les méthodes de l'invention à spécificité antigénique et/ou à activité cytolytique sélective vis à vis d'une cellule aberrante sur le plan pathologique.
Latest bibliographic data on file with the International Bureau